Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2115 - Elevated levels of 5-HIAA and CgA in Patients with PanNETs from the CLARINET Study

Date

10 Sep 2017

Session

Poster display session

Topics

Neuroendocrine Tumours

Presenters

Alexandria Phan

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

A.T. Phan1, E.M. Wolin2, N. Liyanage3, B. Mirakhur4, S. Pitman Lowenthal4, A. Vinik5, G.A. Fisher, Jr6, M. Pavel7

Author affiliations

  • 1 Medical Oncology, University of New Mexico Comprehensive Cancer Center, 87106 - Albuquerque/US
  • 2 Medical Oncology, Montefiore Einstein Center for Cancer Care, Bronx/US
  • 3 R&d Statistics, Ipsen Innovation, Les Ulis/FR
  • 4 Medical Affairs, Ipsen Biopharmaceuticals, Basking Ridge/US
  • 5 Diabetes Research, Eastern Virginia Medical School, Norfolk/US
  • 6 Medical Oncology, Stanford University, Stanford/US
  • 7 Gastroenterology And Hepatology, Endocrinology & Metabolic Diseases, Charité University Medicine Berlin, 13353 - Berlin/DE
More

Resources

Abstract 2115

Background

While carcinoids frequently synthesize, and secrete serotonin into the circulation, and 5-HIAA is a common biomarker in the carcinoids, measurement of 5-HIAA in non-carcinoid PanNET patients (i.e. no hormone-related symptoms or nonfunctional) is not routinely recommended by international guidelines. The incidence of serotonin-producing PanNETs may be underestimated, with potential impact on clinical outcome when serotonin levels remain elevated. We sought to characterize 5-HIAA and CgA levels in PanNET patients who participated in the large placebo-controlled phase III CLARINET Study.

Methods

Evaluable data available for urinary 5-HIAA and serum CgA for patients with PanNET in CLARINET study were analyzed. Urinary 5-HIAA and Serum CgA were assessed at baseline and every 12 weeks thereafter through Week 96. Changes in urinary 5-HIAA and serum CgA levels were calculated using a non-parametric Wilcoxon 2-sample test. Biochemical response for urinary 5-HIAA or serum CgA was defined as baseline >upper limit of normal (ULN, 41.6 µmol/d 5-HIAA; 98.1 µg/L CgA) and ≥50% decrease from baseline or a decrease to a value ≤ULN on study.

Results

91/204 patients in CLARINET had PanNETs. Evaluable data for urinary 5-HIAA and serum CgA concentrations were available in 79 and 88 patients, respectively. A substantial number of patients with PanNET had elevated (>ULN) urinary 5-HIAA levels (21/79; 27%) and/or serum CgA (63/88; 72%). Among the 21 PNET patients with baseline 5-HIAA >ULN, biochemical response was achieved in 85% (11/13) lanreotide-treated patients compared with 63% (5/8) in patients on placebo at the last available value (p = 0.33). Among patients with baseline CgA >ULN, biochemical response was achieved in 66% (19/29) of lanreotide vs. 18% (6/34) of placebo-treated patients (p = 0.0002). Limited sample sizes precluded robust analysis for statistically significant differences in the lanreotide vs. the placebo group among patients with elevated biomarkers at baseline and biochemical response.

Conclusions

The percentage of patients with elevated urinary 5-HIAA was unexpected. The concept of PanNET and secretion of serotonin may need to be redefined. The potential of 5-HIAA and CgA as biomarkers of response and follow-up in nonfunctioning PanNET is alluring, but requires further study. Data from additional prospective studies are needed to impact clinical practice guidelines.

Clinical trial identification

NCT00353496

Legal entity responsible for the study

Ipsen Biopharmaceuticals

Funding

Ipsen Biopharmaceuticals r A.T. Phan: Consultant/Advisor: Ipsen, Novartis; speakers’ bureau: Celgene, Genentech, Eli Lilly, Ipsen, Novartis; research support: Incyte, Ipsen, Lexicon, Novartis, Sanofi. E.M. Wolin: Consultant/Advisor: Celgene, Ipsen, Novartis, Pfizer; research support: Ipsen (Inst), Novartis (Inst), Pfizer (Inst). N. Liyanage: Employee of Ipsen. B. Mirakhur: Employee of Ipsen Biopharmaceuticals. S. Pitman Lowenthal: Employee of Ipsen Biopharmaceuticals. A. Vinik: Const/Advisor: Isis, Merck, Neurometrix, Pamlab, Pfizer; speakers bureau: Merck, Pamlab; research support: BMS, Celgene, Eli Lilly, Medivation, Newlink Genetics, Novartis, Pharmaceutical Research Associates, Polaris, PRA International, Tercica, XBiotech. G.A. Fisher, Jr: Consultant/Advisor: Genentech, Ipsen; research support: BMS, Celgene, Lilly, Ipsen, Medivation, Newlink Genetics, Novartis, Pharmaceutical Research Associates, Polaris, PRA International, Tercica, XBiotech; stock ownership: Seattle Genetics. M. Pavel: Consultant/Advisor: Ipsen, Lexicon, Novartis, Pfizer; research support: Novartis.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.